Compression Therapy of the Lower Limbs in Patients With Decompensated Heart Failure

NCT ID: NCT06418932

Last Updated: 2024-10-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

106 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-27

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Randomized 1:1 multicenter double-blind clinical investigation evaluating the efficacy and safety of compression therapy of the lower limbs plus parenteral administration of diuretics vs. administration of parenteral diuretics alone (standard treatment) in patients with decompensated HF and predominantly systemic tissue congestion and absence of intravascular systemic congestion.

Patients will be assigned to standard treatment (parenteral administration of furosemide) versus parenteral administration of furosemide plus lower limb compression therapy for up to 72 hours. The dose of furosemide in all participants will be based on the clinical judgment of the responsible healthcare professional.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will be assigned to standard treatment (parenteral administration of furosemide) versus parenteral administration of furosemide plus lower limb compression therapy for a maximum of 72 hours. The dose of furosemide in all participants will be based on the clinical judgment of the responsible health professional.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
Sham procedure. Blinded to treatment allocation. The investigator and the patients will be blinded to treatment assignments. For this purpose, a restraint system will be used which will be applied to the lower limbs and will mask the assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Compressive

Compressive therapy of the lower limbs plus parenteral administration of diuretics

Group Type EXPERIMENTAL

UrgoK2 / UrgoK2 Lite

Intervention Type DEVICE

Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.

Control

Parenteral diuretics alone

Group Type ACTIVE_COMPARATOR

Controll

Intervention Type OTHER

Administration of parenteral diuretics only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UrgoK2 / UrgoK2 Lite

Multicomponent compressive bandage system consisting of an internal bandage of short traction and an external cohesive bandage of long traction, with pressure indicators on both bandages, which provides a sustained ankle pressure of \~20/40mmHg.

Intervention Type DEVICE

Controll

Administration of parenteral diuretics only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years or older.
* Patient with clinical judgment of acute decompensated heart failure in the first 96 hours from the start of parenteral diuretic treatment.
* Patient treated with furosemide at least 40 mg in the last 24 hours.
* NT-proBNP levels\>1000 pg/ml at least 1 time since the onset of decompensation.
* Presence of tibio-malleolar edema at least grade II/IV at the time of inclusion.
* Inferior vena cava (IVC) diameter on ultrasonography ≤21 mm at the time of the "screening" visit.

Exclusion Criteria

* Being admitted to the Intensive Care Unit.
* Renal transplant, chronic renal failure stage 5 (eGFR \<15 ml/min/1.73m2) or being included in dialysis program (peritoneal/hemodialysis) or in need of ultrafiltration.
* Absence of peripheral pulses.
* Ankle brachial index (ABI) \<0.9.
* History of severe peripheral artery disease.
* Previous intolerance to compressive bandaging.
* HF secondary to acute myocardial infarction.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundación para la Investigación del Hospital Clínico de Valencia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de Denia

Denia, Alicante, Spain

Site Status RECRUITING

Hospital Universitario de Torrevieja

Torrevieja, Alicante, Spain

Site Status NOT_YET_RECRUITING

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status NOT_YET_RECRUITING

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status RECRUITING

Hospital Puerta de Hierro

Madrid, , Spain

Site Status RECRUITING

Hospital Clínico Universitario Virgen de la Arrixaca

Murcia, , Spain

Site Status RECRUITING

Hospital General de Valencia

Valencia, , Spain

Site Status RECRUITING

Hospital Clínico Universitario de Valencia

Valencia, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sergio Luengo Pérez

Role: primary

651593649

María Montesinos Aldeguer

Role: primary

670257680

Clara Simón Ramón

Role: primary

678220578

Pau Llàcer Iborra

Role: primary

639202963

Juan Carlos López-Azor

Role: primary

628026462

Francisco José Pastor Pérez

Role: primary

932 91 90 00

José Pérez Silvestre

Role: primary

630786752

Julio JN Nuñez

Role: primary

652856689 ext. +34

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COMPRESSION-HF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Provocative Tests for HFpEF
NCT06309550 RECRUITING